Katherine M. Digianantonio

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh et al. · Clinical Cancer Research · 2024 · 160 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

A de novo enzyme catalyzes a life-sustaining reaction in Escherichia coli

Ann Donnelly, Grant S. Murphy, Katherine M. Digianantonio et al. · Nature Chemical Biology · 2018 · 61 citations

Life Sciences, Biochemistry, Microbiology +14

Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules

Christopher M. Hickey, Katherine M. Digianantonio, Kurt Zimmermann et al. · Nature Structural & Molecular Biology · 2024 · 58 citations

Life Sciences, Biochemistry, Molecular Biology +11

MxB Restricts HIV-1 by Targeting the Tri-hexamer Interface of the Viral Capsid

Sarah Smaga, Chaoyi Xu, Brady J. Summers et al. · Structure · 2019 · 52 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +12

A protein constructed de novo enables cell growth by altering gene regulation

Katherine M. Digianantonio, Michael H. Hecht · Proceedings of the National Academy of Sciences · 2016 · 44 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15